Professor Krzysztof Palczewski and team are working on therapies for people with diseases that lead to loss of eyesight. At this point, gene editing techniques allow to repair genetic mutations in living cells, including the eye. 'We need 5-7 years before human trials could begin', he says.
Drug repurposing trials for COVID reported inconsistent results. Scientists from the Jagiellonian University show that these inconsistencies could have been caused by random differences between treatment and control groups, as well as incorrect statistical analysis, and not errors in research practices.